PTC Therapeutics Inc (PTCT) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.

Total Revenue Chart for PTC Therapeutics Inc

PTC Therapeutics Inc (PTCT) revenue for FY2025 was USD 1.7B, a 114.5% change from FY2024. PTC Therapeutics Inc's revenue grew from USD 1.6M in 2004 to USD 1.7B in 2025 (107661.8% over 21 years). Earnings per share grew from USD 1.31 in 2011 to USD -7.79 in 2022 (-697.1%). Revenue compound annual growth rate: 5-year CAGR of 35.4%, 10-year CAGR of 47.0%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$4.94B
Implied Share Price
$59.24
Enterprise Value
$3.67B
Revenue (TTM)
$1.01B
EBITDA
$171.22M
Profit Margin
-3.81%
Trailing P/E
—
Forward P/E
22.73
Price/Book (MRQ)
1743.27
Price/Sales (TTM)
4.90
EV/EBITDA
21.15
EV/Revenue
3.64
Dividend Yield
—
Book Value
$-1.99
Free Cash Flow (FY2025)
$411.18M
Free Cash Flow Yield
8.32%

Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.